Cart
sales@molnova.com
Angiotensinogen (1-14), Porcine
CAS No. 20845-02-7
Angiotensinogen (1-14), Porcine( ——— )
Catalog No. M40862 CAS No. 20845-02-7
Angiotensinogen (1-14) porcine is a polypeptide, which is the N-terminal fragment of angiotensinogen, including amino acid residues 1 to 14.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAngiotensinogen (1-14), Porcine
-
NoteResearch use only, not for human use.
-
Brief DescriptionAngiotensinogen (1-14) porcine is a polypeptide, which is the N-terminal fragment of angiotensinogen, including amino acid residues 1 to 14.
-
DescriptionAngiotensinogen (1-14) porcine is a polypeptide, which is the N-terminal fragment of angiotensinogen, including amino acid residues 1 to 14.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number20845-02-7
-
Formula Weight1759.1
-
Molecular FormulaC85H123N21O20
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Stephen D, et al. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. The Prostate.Volume34,?Issue1.1 January 1998 Pages?44-50.
molnova catalog
related products
-
Pam3CSK4 TFA
Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) Agonist with an EC50 of 0.47 ng/mL for human TLR1/2.
-
TRi-1
TRi-1 is irreversible inhibitor of?cytosolic thioredoxin reductase 1 (TXNRD1) with an?IC50?of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy.
-
pep2-SVKI
Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluA2 AMPA receptor subunit. Disrupts binding of GluA2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and protein interacting with C kinase (PICK1). Increases amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD).
